Research Article
BibTex RIS Cite

İnflamatuar bağırsak hastalığında non-alkolik yağlı karaciğer hastalığı sıklığı

Year 2021, Volume: 20 Issue: 1, 27 - 31, 14.05.2021
https://doi.org/10.17941/agd.799316

Abstract

Giriş ve Amaç: Non-alkolik yağlı karaciğer hastalığı, inflamatuar bağırsak hastalığında (İBH) yaygındır. Bu çalışmanın amacı İBH’da prevalansını eşleştirilmiş bir kontrol grubuyla karşılaştırıldığında değerlendirmek ve İBH’da non-alkolik yağlı karaciğer hastalığı ile ilişkili özellikleri tanımlamaktır.
Gereç ve Yöntem: Karın ağrısı nedeniyle gastroenteroloji poliklinik kontrollerinde USG tetkiki yapılan 225 İBH tanılı olgunun tıbbi kayıtları geriye dönük olarak incelendi. Bu olgular yaş ve vücut kitle indeksi (VKİ) ve diabetes mellitus (DM) varlığı açısından eşleştirilmiş İBH olmayan 70 kontrol grubuyla karşılaştırıldı. Batın USG verileri, karaciğerdeki hepatosteatoz varlığı veya yokluğu açısından analiz edildi.
Bulgular: Çalışma popülasyonu içinde non-alkolik yağlı karaciğer hastalığı oranı %38,3 saptandı. İBH hasta grubunda kontrol grubuna göre anlamlı olarak daha yüksek oranda non-alkolik yağlı karaciğer hastalığı izlendi (%43,3’e karşı %25; p=0,004). Ülseratif kolit alt grubunda kontrol grubuna göre anlamlı olarak daha yüksek oranda non-alkolik yağlı karaciğer hastalığı izlendi (%43,9 karşı %25, p=0,007). Crohn hastalığı alt grubunda kontrol grubuna göre anlamlı olarak daha yüksek oranda yağlı karaciğer izlendi (%42,4 karşı %25, p=0,015). İBH varlığı, DM varlığı, VKİ>25 üzerinde olması bağımsız olarak non-alkolik yağlı karaciğer hastalığı gelişimi riskini arttırdığı saptandı.
Sonuç: İBH varlığı non-alkolik yağlı karaciğer hastalığı gelişim riskini artırmaktadır. İBH olgularında sistemik iltihaplanma ve bağırsak mikrobiyomunun değişmesi non-alkolik yağlı karaciğer hastalığı gelişiminde potansiyel nedensel faktörler olarak önerilmiştir, ancak patofizyolojiyi aydınlatmak için daha fazla çalışmaya ihtiyaç duyulacaktır.

References

  • 1. Le MH, Devaki P, Ha NB, et al. Prevalence of non-alcoholic fatty liver disease and risk factors for advanced fibrosis and mortality in the United States. PLoS One. 2017; 12(3): e0173499. Epub 2017/03/28.
  • 2. Ratziu V, Bellentani S, Cortez-Pinto H, Day C, Marchesini G. A position statement on NAFLD/NASH based on the EASL 2009 special conference. J Hepatol 2010; 53: 372-384.
  • 3. Vernon G, Baranova A, Younossi ZM. Systematic review: The epidemiology and natural history of nonalcoholic fatty liver disease and non-alcoholic steatohepatitis in adults. Aliment Pharmacol Ther 2011; 34: 274-285.
  • 4. Younossi ZM, Koenig AB, Abdelatif D, et al. Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology. 2016 Jul;64(1):73-84.
  • 5. Loftus EV, Jr. Clinical epidemiology of inflammatory bowel disease: Incidence, prevalence, and environmental influences. Gastroenterology 2004,126:1504-1517.
  • 6. Saroli Palumbo C, Restellini S, Chao CY, et al. Screening for Nonalcoholic Fatty Liver Disease in Inflammatory Bowel Diseases: A Cohort Study Using Transient Elastography. Inflamm Bowel Dis 2019; 25: 124-133
  • 7. Bessissow T, Le NH, Rollet K, et al. Incidence and Predictors of Nonalcoholic Fatty Liver Disease by Serum Biomarkers in Patients with Inflammatory Bowel Disease. Inflamm Bowel Dis 2016; 22: 1937-1944
  • 8. Nagahori M, Hyun SB, Totsuka T, et al. Prevalence of metabolic syndrome is comparable between inflammatory bowel disease patients and the general population. J Gastroenterol 2010; 45: 1008-1013
  • 9. Principi M, Iannone A, Losurdo G, et al. Nonalcoholic Fatty Liver Disease in Inflammatory Bowel Disease: Prevalence and Risk Factors. Inflamm Bowel Dis. 2018 Jun 8;24(7):1589-1596.
  • 10. Likhitsup A, Dundulis J, Ansari S, et al. Prevalence of non-alcoholic fatty liver disease on computed tomography in patients with inflammatory bowel disease visiting an emergency department. Ann Gastroenterol. 2019 May-Jun;32(3):283-286.
  • 11. Carr RM, Oranu A, Khungar V. Nonalcoholic Fatty Liver Disease: Pathophysiology and Management. Gastroenterol Clin North Am 2016; 45: 639-652
  • 12. Sanyal D, Mukherjee P, Raychaudhuri M, et al. Profile of liver enzymes in non-alcoholic fatty liver disease in patients with impaired glucose tolerance and newly detected untreated type 2 diabetes. Indian J Endocrinol Metab. 2015; 19(5):597–601.
  • 13. Younossi ZM, Koenig AB, Abdelatif D, et al. Global epidemiology of nonalcoholic fatty liver diseasemeta-analytic assessment of prevalence, incidence, and outcomes. Hepatology 2016;64:73-84.
  • 14. Bargiggia S, Maconi G, Elli M, et al. Sonographic prevalence of liver steatosis and biliary tract stones in patients with inflammatory bowel disease: study of 511 subjects at a single center. J Clin Gastroenterol 2003;36:417-420.
  • 15. Sourianarayanane A, Garg G, Smith TH, et al. Risk factors of non-alcoholic fatty liver disease in patients with inflammatory bowel disease. J Crohns Colitis 2013;7:e279-e285.
  • 16. Bessissow T, Le NH, Rollet K, et al. Incidence and predictors of nonalcoholic fatty liver disease by serum biomarkers in patients with inflammatory bowel disease. Inflamm Bowel Dis 2016;22:1937-1944.
  • 17. Bosch DE, Yeh MM. Primary sclerosing cholangitis is protective against nonalcoholic fatty liver disease in inflammatory bowel disease. Hum Pathol 2017;69:55-62.
  • 18. Carr RM, Patel A, Bownik H, et al. Intestinal inflammation does not predict nonalcoholic fatty liver disease severity in inflammatory bowel disease patients. Dig Dis Sci 2017;62:1354-1361.
  • 19. McGowan CE, Jones P, Long MD, Barritt ASt. Changing shape of disease: nonalcoholic fatty liver disease in Crohn’s disease-a case series and review of the literature. Inflamm Bowel Dis. 2012; 18(1):49-54.
  • 20. Bessissow T, Le NH, Rollet K, Afif W, Bitton A, Sebastiani G. Incidence and Predictors of Nonalcoholic Fatty Liver Disease by Serum Biomarkers in Patients with Inflammatory Bowel Disease. Inflamm Bowel Dis. 2016; 22(8):1937–44.
Year 2021, Volume: 20 Issue: 1, 27 - 31, 14.05.2021
https://doi.org/10.17941/agd.799316

Abstract

References

  • 1. Le MH, Devaki P, Ha NB, et al. Prevalence of non-alcoholic fatty liver disease and risk factors for advanced fibrosis and mortality in the United States. PLoS One. 2017; 12(3): e0173499. Epub 2017/03/28.
  • 2. Ratziu V, Bellentani S, Cortez-Pinto H, Day C, Marchesini G. A position statement on NAFLD/NASH based on the EASL 2009 special conference. J Hepatol 2010; 53: 372-384.
  • 3. Vernon G, Baranova A, Younossi ZM. Systematic review: The epidemiology and natural history of nonalcoholic fatty liver disease and non-alcoholic steatohepatitis in adults. Aliment Pharmacol Ther 2011; 34: 274-285.
  • 4. Younossi ZM, Koenig AB, Abdelatif D, et al. Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology. 2016 Jul;64(1):73-84.
  • 5. Loftus EV, Jr. Clinical epidemiology of inflammatory bowel disease: Incidence, prevalence, and environmental influences. Gastroenterology 2004,126:1504-1517.
  • 6. Saroli Palumbo C, Restellini S, Chao CY, et al. Screening for Nonalcoholic Fatty Liver Disease in Inflammatory Bowel Diseases: A Cohort Study Using Transient Elastography. Inflamm Bowel Dis 2019; 25: 124-133
  • 7. Bessissow T, Le NH, Rollet K, et al. Incidence and Predictors of Nonalcoholic Fatty Liver Disease by Serum Biomarkers in Patients with Inflammatory Bowel Disease. Inflamm Bowel Dis 2016; 22: 1937-1944
  • 8. Nagahori M, Hyun SB, Totsuka T, et al. Prevalence of metabolic syndrome is comparable between inflammatory bowel disease patients and the general population. J Gastroenterol 2010; 45: 1008-1013
  • 9. Principi M, Iannone A, Losurdo G, et al. Nonalcoholic Fatty Liver Disease in Inflammatory Bowel Disease: Prevalence and Risk Factors. Inflamm Bowel Dis. 2018 Jun 8;24(7):1589-1596.
  • 10. Likhitsup A, Dundulis J, Ansari S, et al. Prevalence of non-alcoholic fatty liver disease on computed tomography in patients with inflammatory bowel disease visiting an emergency department. Ann Gastroenterol. 2019 May-Jun;32(3):283-286.
  • 11. Carr RM, Oranu A, Khungar V. Nonalcoholic Fatty Liver Disease: Pathophysiology and Management. Gastroenterol Clin North Am 2016; 45: 639-652
  • 12. Sanyal D, Mukherjee P, Raychaudhuri M, et al. Profile of liver enzymes in non-alcoholic fatty liver disease in patients with impaired glucose tolerance and newly detected untreated type 2 diabetes. Indian J Endocrinol Metab. 2015; 19(5):597–601.
  • 13. Younossi ZM, Koenig AB, Abdelatif D, et al. Global epidemiology of nonalcoholic fatty liver diseasemeta-analytic assessment of prevalence, incidence, and outcomes. Hepatology 2016;64:73-84.
  • 14. Bargiggia S, Maconi G, Elli M, et al. Sonographic prevalence of liver steatosis and biliary tract stones in patients with inflammatory bowel disease: study of 511 subjects at a single center. J Clin Gastroenterol 2003;36:417-420.
  • 15. Sourianarayanane A, Garg G, Smith TH, et al. Risk factors of non-alcoholic fatty liver disease in patients with inflammatory bowel disease. J Crohns Colitis 2013;7:e279-e285.
  • 16. Bessissow T, Le NH, Rollet K, et al. Incidence and predictors of nonalcoholic fatty liver disease by serum biomarkers in patients with inflammatory bowel disease. Inflamm Bowel Dis 2016;22:1937-1944.
  • 17. Bosch DE, Yeh MM. Primary sclerosing cholangitis is protective against nonalcoholic fatty liver disease in inflammatory bowel disease. Hum Pathol 2017;69:55-62.
  • 18. Carr RM, Patel A, Bownik H, et al. Intestinal inflammation does not predict nonalcoholic fatty liver disease severity in inflammatory bowel disease patients. Dig Dis Sci 2017;62:1354-1361.
  • 19. McGowan CE, Jones P, Long MD, Barritt ASt. Changing shape of disease: nonalcoholic fatty liver disease in Crohn’s disease-a case series and review of the literature. Inflamm Bowel Dis. 2012; 18(1):49-54.
  • 20. Bessissow T, Le NH, Rollet K, Afif W, Bitton A, Sebastiani G. Incidence and Predictors of Nonalcoholic Fatty Liver Disease by Serum Biomarkers in Patients with Inflammatory Bowel Disease. Inflamm Bowel Dis. 2016; 22(8):1937–44.
There are 20 citations in total.

Details

Primary Language Turkish
Subjects Health Care Administration
Journal Section Articles
Authors

Emre Gerçeker

Serkan Cerrah

Ahmed Ramiz Baykan

Publication Date May 14, 2021
Published in Issue Year 2021 Volume: 20 Issue: 1

Cite

APA Gerçeker, E., Cerrah, S., & Baykan, A. R. (2021). İnflamatuar bağırsak hastalığında non-alkolik yağlı karaciğer hastalığı sıklığı. Akademik Gastroenteroloji Dergisi, 20(1), 27-31. https://doi.org/10.17941/agd.799316

test-5